Orlistat
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Empros Pharma AB · Phase 2 · Completed · Enrollment 200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity + T2D | n/r | 12 | n/r | n/r |
| Orlistat | Obesity + T2D | n/r | 12 | n/r | n/r |